在慢性阻塞性肺病的小鼠模型中,Sirtuin 3 缺乏会加剧肺气和肺炎
Taro Ishimori1, Minako Saito1, Masaaki Yuki1
1Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
概括
锡尔图因3 (SIRT3) 能够预防慢性阻塞性肺病 (COPD). 减少SIRT3会使COPD症状恶化,而其过度表达会减轻疾病,突出SIRT3作为COPD潜在的治疗点.
科学领域:
- 肺部医学 肺部医学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 慢性阻塞性肺病 (COPD) 是一种进展性肺病,与吸烟导致的氧化压力有关.
- 已知Sirtuin 3 (SIRT3) 能调节活性氧物种,但其在COPD病变发生过程中的具体作用尚不清楚.
研究的目的:
- 调查Sirtuin 3 (SIRT3) 在慢性阻塞性肺病 (COPD) 病原发生中的作用.
- 确定SIRT3是否对COPD具有保护作用,并探索其治疗潜力.
主要方法:
- 评估了COPD肺部SIRT3表达和吸烟对呼吸道上皮的影响.
- 利用SIRT3淘汰赛 (KO) 和转基因过度表达 (OE) 的小鼠使用弹性酶和脂多糖化物来建模COPD.
- 对呼吸道上皮细胞进行了体外研究,以检查SIRT3对炎症,氧化应激和亡的影响.
主要成果:
- 慢性肺炎肺部显示SIRT3表达减少;吸烟进一步抑制了呼吸道上皮质中的SIRT3.
- SIRT3 KO小鼠表现出亡标记的增加和肺气的恶化,特别是在老年和COPD模型小鼠中.
- 在COPD模型中,SIRT3 OE小鼠表现出缓解的肺变化,而在体外,SIRT3缺乏会加剧炎症,氧化应激和亡.
结论:
- 锡尔图因3 (SIRT3) 在慢性阻塞性肺病 (COPD) 病原发生过程中起着至关重要的保护作用.
- 缺少SIRT3会加剧COPD的关键特征,包括炎症,氧化应激和亡.
- SIRT3代表了一种有前途的新型治疗点,用于治疗COPD.
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
5.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
5.0K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
4.0K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.0K
01:23Chronic Obstructive Pulmonary Disease I: Introduction
33
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
33
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
48
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
48
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
40
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
40